Literature DB >> 1517571

In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.

S E Karp1, P Hwu, A Farber, N P Restifo, M Kriegler, J J Mulé, S A Rosenberg.   

Abstract

We have previously demonstrated that murine tumor cells transduced with a retrovirus containing the cDNA encoding wild-type human TNF regress in vivo when injected into immunocompetent mice; this regression is T cell mediated. To determine whether membrane-associated or secreted TNF was responsible for tumor regression, we transduced a cloned murine fibrosarcoma 205 F4 with retroviruses encoding modified human TNF genes. The cloned tumor lines of one retroviral transduction expressed only membrane bound 26-kDa TNF. This TNF could not be cleaved or secreted, but was present on the cell surface. A second retrovirus caused the expression of only secretory 17-kDa TNF, as the transmembrane domain of the cDNA was deleted. The TNF produced by tumor cells transduced with either retroviral vector was functional in vitro as direct lysis of the TNF-sensitive target L929 by transduced tumor cells was demonstrated. The TNF present on 26-kDa expressing tumors was membrane bound as supernatants from cultured 17-kDa TNF expressing tumor cells but not 26-kDa TNF expressing tumors mediated the lysis of L929 cells. Both tumors were injected s.c. into syngeneic mice and tumor growth was measured serially. In repeated experiments, 26-kDa TNF expressing tumors grew progressively in all mice. In contrast, 17-kDa TNF expressing tumors grew for 10 days and then regressed with all animals free of tumor at 28 days. Tumor regression was abrogated by in vivo injection of an anti-TNF antibody. Similar results were obtained in a second tumor model, 203 E4. Thus regression of TNF transduced tumors in vivo requires secretion of TNF, as membrane-bound TNF is insufficient to elicit the host response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517571      PMCID: PMC2121327     

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

Authors:  M Kriegler; C Perez; K DeFay; I Albert; S D Lu
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

2.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.

Authors:  P Scheurich; B Thoma; U Ucer; K Pfizenmaier
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

3.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

4.  Tumour necrosis factor-like activity on paraformaldehyde-fixed monocyte monolayers.

Authors:  T Espevik; J Nissen-Meyer
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

5.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

6.  Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.

Authors:  L B Owen-Schaub; J U Gutterman; E A Grimm
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

7.  Immunomodulatory properties of recombinant murine and human tumor necrosis factor.

Authors:  J E Talmadge; H Phillips; M Schneider; T Rowe; R Pennington; O Bowersox; B Lenz
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

8.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.

Authors:  E A Havell; W Fiers; R J North
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

9.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  4 in total

1.  Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells.

Authors:  Chinh N Tran; Steven K Lundy; Peter T White; Judith L Endres; Christopher D Motyl; Raj Gupta; Cailin M Wilke; Eric A Shelden; Kevin C Chung; Andrew G Urquhart; David A Fox
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

Review 2.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

3.  Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.

Authors:  F M Marincola; S Ettinghausen; P A Cohen; L B Cheshire; N P Restifo; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

4.  The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation.

Authors:  G Aversa; J Punnonen; J E de Vries
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.